Private equity investment in healthcare scaled aggressively over the past decade—500+ deals annually and ~$150B at peak. The model was consistent: consolidation drove pricing power, labor costs were manageable and leverage amplified returns. That model is now under pressure.
Historically, PE ownership drove 7%–16% price increases post-acquisition, but insurers and government payors are now pushing back, limiting margin expansion through pricing and tightening reimbursement. At the same time, operating performance is weakening due to higher labor costs, shifting payer mix, and operational inefficiencies, reducing cash flow conversion. Many platforms are also carrying the weight of leverage, dividend recaps, and real estate monetization, creating fixed obligations that current performance doesn’t fully support.
Meanwhile, regulators are focusing on consolidation. The FTC is targeting PE-backed roll-ups, directly challenging a core value creation strategy. The model that once translated consolidation into predictable margin expansion is now facing resistance.
For funds holding healthcare investments beyond plan, the issue is no longer timing, it’s whether the asset can support an exit.
Healthcare demand is growing. The industry recorded $5.3T in 2024 and expected to exceed $7T in the next decade. The issue isn’t demand, it’s alignment.
Value today is built through execution:
- Aligning service mix with reimbursement
- Rebuilding margins without degrading care
- Converting activity into cash flow
The firms that act decisively will preserve value. Those who wait may find the gap between underwritten and realizable value continues to widen.